A phase I trial (NCT01919398) assessed the efficacy of taladegib in several advanced solid tumors and suggested that it is effective only in BCC with an estimated ORR of 46.8%.546 This clinical trial also indicated that taladegib could benefit patients who were resistant to SMO inhibitors. Here, SMO is linked to skin basal cell carcinoma.